Johnson & Johnson's COVID-19 Vaccine Less Effective Against Hospitalization, French Study Shows

According to a large French study, the risk of hospitalization after vaccination with Johnson & Johnson's JNJ COVID-19 vaccine was about five times higher than those who received the Pfizer Inc PFEBioNTech SE's BNTX shot.

The researchers reported the findings in JAMA Network Open. The study included nearly 7 million recipients of the two-dose mRNA vaccine from Pfizer/BioNTech and an equal number of similar people who received the one-shot vector-based JNJ vaccine. 

The data exhibited the effectiveness of the vaccines at preventing hospitalization at 92% for Pfizer/BioNTech's shots versus 59% for the J&J vaccine. 

Related: Final Analysis Show Johnson & Johnson's COVID-19 Offers Only 52.9% Protection.

"These results strengthen the evidence" in favor of giving an mRNA booster shot to people who initially received the J&J vaccine, the authors conclude.

Also See: Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations.

Price Action: JNJ shares traded 0.89% higher at $167.52, PFE shares are up 1.47% at $48.40, BNTX stock is down 2.42% at $143.39 during the market session on the last check Thursday.

Photo by Johaehn from Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!